InvestorsHub Logo
Followers 12
Posts 471
Boards Moderated 0
Alias Born 06/20/2020

Re: krobar post# 336660

Wednesday, 12/16/2020 10:36:07 AM

Wednesday, December 16, 2020 10:36:07 AM

Post# of 403134
I'm holding at this point in the hopes for a pop on a good PR and will sell a portion of my position.

I cannot put on blinders and ignore the amount of dilution waiting in the wings. I also cannot put on blinders as to the validity of the RBL testing. Imo the results of the RBL testing are not clinically reproducible. The testing was done at a concentration of 10µM which equates to an IV dose of 0.78 mg/kg. As we saw from the ABSSSI P-2b presentation in 2015, a single dose of 0.80 mg/kg resulted in hypertension >160 mmHg in 17% of the subjects. Given that the clinical trial is supposed to treat hospitalized patients already in respiratory distress (where elevated blood pressure is a problem) this is a big red flag imo. I expect they will use a significantly lower dose and that will reduce efficacy.

But given the market cap <$60m a well-written PR could pop the stock.

I invested in this company because of kevetrin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News